Quick Answer
Adaptive Biotechnologies Corp reported Operating Income Loss of -$57.12 million for the year ending 2025.
- Adaptive Biotechnologies Corp showed an increase of +64.9% in Operating Income Loss from 2024 to 2025.
- This data is from Adaptive Biotechnologies Corp's annual report (Form 10-K), filed with the SEC on February 26, 2026.
- XBRL data for this metric is available from 2017 to 2025 (9 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 9 years of available data (2017 to 2025), Adaptive Biotechnologies Corp's Operating Income Loss has declined by 28.4%.
- Historical annual values: Fiscal year 2025: -$57.12 million | Fiscal year 2024: -$162.55 million | Fiscal year 2023: -$227.04 million | Fiscal year 2022: -$200.19 million | Fiscal year 2021: -$208.97 million | Fiscal year 2020: -$152.82 million | Fiscal year 2019: -$78.39 million | Fiscal year 2018: -$49.76 million | Fiscal year 2017: -$44.48 million.
- Data sourced from SEC EDGAR public filings as of June 22, 2026.
Last verified: